206 related articles for article (PubMed ID: 33201771)
1. Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 Studies.
Felice VG; Efimova E; Izmailyan S; Napolitano LM; Chopra T
Surg Infect (Larchmt); 2021 Jun; 22(5):556-561. PubMed ID: 33201771
[No Abstract] [Full Text] [Related]
2. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
[TBL] [Abstract][Full Text] [Related]
3. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
[TBL] [Abstract][Full Text] [Related]
4. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.
Solomkin JS; Ramesh MK; Cesnauskas G; Novikovs N; Stefanova P; Sutcliffe JA; Walpole SM; Horn PT
Antimicrob Agents Chemother; 2014; 58(4):1847-54. PubMed ID: 24342651
[TBL] [Abstract][Full Text] [Related]
5. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
Solomkin JS; Sway A; Lawrence K; Olesky M; Izmailyan S; Tsai L
Future Microbiol; 2019 Oct; 14():1293-1308. PubMed ID: 31570004
[No Abstract] [Full Text] [Related]
6. Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials.
Asempa TE; Izmailyan S; Lawrence K; Nicolau DP
Open Forum Infect Dis; 2020 Dec; 7(12):ofaa548. PubMed ID: 33365356
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
Lan SH; Chang SP; Lai CC; Lu LC; Chao CM
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31212991
[TBL] [Abstract][Full Text] [Related]
8. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
[TBL] [Abstract][Full Text] [Related]
9. Eravacycline: A Review in Complicated Intra-Abdominal Infections.
Scott LJ
Drugs; 2019 Feb; 79(3):315-324. PubMed ID: 30783960
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Eravacycline: A Novel Fluorocycline.
Alosaimy S; Abdul-Mutakabbir JC; Kebriaei R; Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2020 Mar; 40(3):221-238. PubMed ID: 31944332
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eravacycline: A meta-analysis.
Eljaaly K; Ortwine JK; Shaikhomer M; Almangour TA; Bassetti M
J Glob Antimicrob Resist; 2021 Mar; 24():424-428. PubMed ID: 33621690
[TBL] [Abstract][Full Text] [Related]
13. Eravacycline for the treatment of patients with bacterial infections.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
[TBL] [Abstract][Full Text] [Related]
14. Eravacycline, a newly approved fluorocycline.
Lee YR; Burton CE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
[TBL] [Abstract][Full Text] [Related]
15. Eravacycline for the treatment of intra-abdominal infections.
Bassetti M; Righi E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1575-84. PubMed ID: 25251475
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.
Mazuski JE; Wagenlehner F; Torres A; Carmeli Y; Chow JW; Wajsbrot D; Stone GG; Irani P; Bharucha D; Cheng K; Tawadrous M
Infect Dis Ther; 2021 Dec; 10(4):2399-2414. PubMed ID: 34374952
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
19. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W; Deng T; Li S; Shu Y; Wu Y
BMC Infect Dis; 2023 Apr; 23(1):256. PubMed ID: 37085768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
